Incyte Corporation (INCY)

業務介紹

因特賽特公司是一家生物製藥公司,專注於在美國和國際上發現、開發和商業化專有療法。該公司提供以下產品:

JAKAFI,用於治療骨髓纖維化和真性多紅血球增多症;
PEMAZYRE,一種纖維母細胞生長因子受體激酶抑制劑,可作為各種液體和實體瘤中的致癌驅動因子;
ICLUSIG,一種激酶抑制劑,用於治療慢性骨髓性白血病和費城染色體陽性急性淋巴細胞白血病。

該公司的臨床階段產品包括:

ruxolitinib,用於治療類固醇難治性慢性移植物抗宿主病;
itacitinib,正處於II/III期臨床試驗,用於治療初發性慢性移植物抗宿主病;
pemigatinib,用於治療膀胱癌、膽管癌、骨髓增殖綜合症和腫瘤無關。

此外,該公司正在開發Parsaclisib,正處於II期臨床試驗,用於治療濾泡性淋巴瘤、邊緣區淋巴瘤和套細胞淋巴瘤。該公司還在開發Retifanlimab,正處於II期臨床試驗,用於治療MSI-high子宮內膜癌、默克爾細胞癌和肛門癌,以及非小細胞肺癌患者。

該公司與諾華國際藥業有限公司、礼來公司、Agenus Inc.、Calithera Biosciences, Inc、MacroGenics, Inc.、Merus N.V.、Syros Pharmaceuticals, Inc.、創新生物股份有限公司、再鋒有限公司、Cellenkos, Inc.和Nimble Therapeutics等公司有合作協議,並與MorphoSys AG和Xencor, Inc.有臨床合作,研究tafasitamab、plamotamab和lenalidomide的組合療法,用於復發或難治性彌漫性大B細胞淋巴瘤和復發或難治性濾泡性淋巴瘤。該公司成立於1991年,總部位於特拉華州威明頓。



Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

公司網址

https://www.incyte.com